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Background: Chronic pancreatitis (CP) is characterized by a chronic inflammation with 
fibrosis and irreversible morphological changes that can result in permanent structural 
changes with a loss of exocrine and endocrine pancreas function. Exocrine dysfunction leads 
to reduced production of pancreatic digestive enzymes which is the reason of maldigestion 
and malabsorption of ingested nutrients like fats, microelements, vitamins and proteins which 
can lead to osteopathy. 
 
Aims: To determine the prevalence of fat-soluble vitamin deficiency in CP patients by a 
meta-analysis. To evaluate the prevalence of osteopenia and osteoporosis in patients with CP 
and investigate the correlation between bone mineral density (BMD) and CP features, and 
vitamin D and pancreatic exocrine insufficiency (PEI). To evaluate the prevalence of PEI in 
patients with Crohn`s disease (CD). To evaluate the prevalence of PEI and gastrointestinal 
symptoms in patients with Sjögren´s syndrome (SS). 
 
Methods: In paper I we performed a systematic review and meta-analysis. MEDLINE was 
searched up to January 2016 for case series and case-control studies reporting of fat-soluble 
vitamin deficiency in CP patients. In paper II, a multicenter cross-sectional study was 
performed in CP patients. Key clinical and biochemical variables were recorded. PEI was 
assessed by fecal elastase (FE-1) and standardized osteodensitometry was performed by 
DEXA. In paper III, patients with CD were recruited at Karolinska University Hospital and 
demographic, clinical and laboratory data were analyzed. PEI was assessed by FE-1. In paper 
IV, a cross-sectional monocenter study including 57 patients with well-characterized primary 
SS. Patients were recruited from the Department for Rheumatology at Karolinska University 
Hospital in Stockholm, Sweden, between June and December 2019. Key clinical 
characteristics were recorded. Pancreatic exocrine insufficiency (PEI) was assessed by fecal 
elastase FE-1 and 13C-mixed triglyceride breath test (13C-MTG-BT). PEI was defined as FE1 
<200 μg/g and a cumulative 13C-exhalation <20.9%, respectively. The presence and severity 
of gastrointestinal symptoms were assessed by a well-established and validated survey on the 
basis of seven-point Likert scale (SSRS/GSRS-IBS). Results of the questionnaire were 




Results: In paper I, twelve studies with 548 patients were included. With a random-effect 
model, the pooled prevalence rate of vitamin A, D and E deficiency were 16.8%, 57.6% and 
29.2% respectively, with considerable heterogeneity (I2 . 75%, 87.1% and 92%). Only one 
study evaluated vitamin K deficiency. The pooled OR for vitamin D deficiency in CP cases 
compared with controls was 1.17 (95% CI 0.77-1.78). Sensitivity analyses showed lower 
prevalence of vitamin A and E, and higher prevalence of vitamin D deficiency in high-quality 
studies. The rate of pancreatic exocrine insufficiency did not seem affect the deficiency rates, 
while the use of different cut-offs influences results and heterogeneity for vitamin E, but not 
A. In paper II, 188 consecutive CP patients were enrolled at 6 centres (67% M; mean age 60 
years). Osteopenia was diagnosed in 42% and osteoporosis in 22% of cases. The underlying 
etiology was alcohol in 43% of cases, and 18% had severe CP. Fifty-three % of patients had 
PEI. The mean value of vitamin D was 21 ng/ml and 56% of cases had vitamin D 
insufficiency. There was no correlation between vitamin D levels and fecal elastase-1 levels 
or the t-score (spine or femur). Alcoholic etiology was associated with higher risk of having 
low levels of fecal elastase-1 (p=0.02) and with lower level of vitamin D (p=0.001) but not 
with osteopenia or osteoporosis. BMI was lower in patients with osteoporosis (p=0.001). In 
paper III, 20 patients were included comprising 13 (65%) males and 7 (35%) females with a 
mean age of 48.3+-1.4 years. The mean duration of CD was 15.7+- years (range 1-40 years). 
There were 11 (55%) patients without history of bowel surgery and 9 (45%) patients after 
ileocecal resection. FE-1 test was normal in all patients. In paper IV, fifty-seven patients with 
primary SS were included in the study, comprising 92% females with a median age of 63 
years. In total, (87%) 50/57 of SS patients were tested for FE-1 and all had normal results. All 
patients who underwent a 13C-MTG-BT (21/57; 37%) had a normal cumulative 13C-exhalation 
(>20.9%). Compared to the control group, significantly more patients suffered from GI 
symptoms (p<0.01 in all 11 items). The same number of patients noted moderate to severe 
loose bowel movements (38%) and constipation (38%). Eleven GI symptom parameters were 
compared to controls, the highest odd ratios were noted for the following moderate to severe 
symptoms: bloating (OR: 27.9, 95% CI: 9.81-91.9), feeling of incomplete emptied bowel after 
defecation (OR 21.4, 95%: 6.95-75.8), and abdominal pain relieved by bowel action (OR 
17.8, 95% CI: 6.04-62.2).  
 
Conclusions: In our meta-analysis, fat-soluble vitamins deficiency is frequent in CP patients, 
but there is considerable heterogeneity between different studies. With regards to vitamin D, 
there are few case-control studies and no apparent increased deficiency risk in CP vs controls. 
 
 
The present data in paper II confirm a high rate of osteopathy in CP patients. There was 
apparently no correlation between BMD, pancreatic exocrine function, severity of chronic 
pancreatitis or vitamin D levels. In paper III, FE-1 was normal in all patients with CD which 
strongly indicated absence of PEI in this group of patients. In paper IV, according to our 
study, the vast majority of SS patients suffered from IBS-like GI symptoms that cannot be 
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1. INTRODUCTION  
 
1.1 Pancreas anatomy and physiology 
 
The pancreas is a digestive gland that is located deep in the retroperitoneum crossing the first 
and second lumbar vertebra of the spine. The pancreas lies between the duodenal C on the 
right and the splenic hilum on the left. Parts of the pancreas termed head, neck, body and the 
tail (Figure 1). The largest part of the pancreas is represented by the pancreatic head. (1) The 






Figure 1. Anatomy of the pancreas. Blausen.com staff (2014). "Medical gallery of Blausen Medical 
2014". WikiJournal of Medicine 1 (2).Creative Commons CC BY. 
 
The pancreas can be divided in the exocrine and endocrine pancreas. The exocrine pancreas 
produces enzymes that are secreted into the gastrointestinal tract, whereas the endocrine 
pancreas synthesizes hormones which have direct access to the blood circulation.  
The exocrine pancreas is represented by acinar cells which are forming a functional unit 
called acinus (Figure 2). Acinar cells are highly specialized polarized cells with a high 
capacity for protein synthesis and produce and actively secrete all pancreatic enzymes that are 
required for digestion (Table 1).  The majority of enzymes are synthesized as inactive pro-






Figure 2. Secretin and cholecystokinin (CCK) are the two main hormones regulating pancreatic 
secretion. Secretin strongly stimulates the production of bicarbonate rich pancreatic juices by its 
effect on the ductular cells of the pancreas but has even a stimulatory effect on acinar cells. CCK 
stimulates production and secretion of pancreatic enzymes. Parasympathetic vagal innervation of the 
pancreas stimulates both enzyme and bicarbonate production. 
From: Sleisenger and Fordtran's Gastrointestinal and Liver Disease 11th edition 2020. With 
permission from Elsevier.  
 
 
Table 1: A large range of different pancreatic enzymes are produced and secreted by acinar cells. 
Inactive proenzymes are activated in the duodenum. All enzymes are stored in intracellular zymogen 
granules to prevent activation in the pancreas.  
From: Sleisenger and Fordtran's Gastrointestinal and Liver Disease 11th edition 2020. With 
permission from Elsevier. 
 
 3 
Several safety systems have emerged during evolution to prevent activation of pancreatic 
proenzymes in the pancreas which would trigger autodigestion resulting in pancreatitis. 
Inactive proenzymes become activated after reaching the duodenum by enterokinase which is 
produced in the duodenum.  Enterokinase-mediated activation of trypsinogen plays a key role 
in the activation process (Figure 3).  
Active trypsin is able to activate several different proenzymes. By contrast, other enzymes of 
the exocrine pancreas are produced in their active forms (amylase, carboxylesterase, DNAse, 
RNAse). The pancreas is the only source for lipase, whereas other enzymes are produced even 
in other organs. For example, salivary glands secrete significant amounts of amylase in order 
to metabolize starch and glycogen. 
Synthesis and secretion of pancreatic enzymes is regulated by the neurohumoral system. 
Innervation of the pancreas by vagal nerves stimulates - via acetylcholine (ACh) – the 
secretion of pancreatic enzymes following increase of intracellular calcium (Ca2+). 
Cholecystokinin (CCK) is the main hormone that stimulates pancreatic enzyme secretion via 
binding to receptors of the acinar cells. A meal passing the stomach and reaching the 
duodenum stimulates CCK release in the duodenum and subsequent pancreatic secretion 
(Figure 4). Other hormones such as Gastrin-releasing peptide (GRP), vasoactive intestinal 
peptide (VIP) and substance P have additional stimulatory function but play a less important 






Figure 3. Inactive proenzymes reaching the 
duodenum by the pancreatic duct system become 
activated by enterokinase which is an 
endopeptidase produced by S-cells in the 
duodenum.  
From: Sleisenger and Fordtran's Gastrointestinal 
and Liver Disease 11th edition 2020. With 





Figure 4. This figure depicts the complex interplay of the humoral and neural regulation of pancreatic 
secretion. Food that reaches the duodenum stimulates specialised cells to liberate secretin and 
cholecystokinin with stimulation of pancreatic secretion. Vagal efferent and afferent loops modulate 
these processes.  
From: Sleisenger and Fordtran's Gastrointestinal and Liver Disease 11th edition 2020. With 
permission from Elsevier.  
 
The pancreatic duct cells secrete approximately 1000 ml alkaline and iso-osmotic pancreatic 
juice every day. Production of a bicarbonate rich fluid is required for buffering of the gastric 
acid enabling optimal activity of pancreatic enzymes.   
 
The endocrine pancreas is represented by the islets of Langerhans comprising five different 
endocrine cell types (alpha, beta, delta, epsilon, and epsilon). These hormone-producing cells 
secrete their hormones directly into the blood circulation (glucagon, insulin, somatostatin, 
ghrelin, and pancreatic polypeptide, respectively). The majority of islets of Langerhans are 
located in the pancreatic head. (3, 4)   
 
1.2 Measurement of exocrine pancreatic function 
 
A variety of different tests were developed to evaluate exocrine function which can be divided 
into direct and indirect function tests (Table 2). Direct tests are characterized by the sampling 
of the pancreatic secretion in the duodenum after placement after duodenal intubation and 
tube placement (by endoscopy or fluoroscopy). After intravenous administration of secretin, 
the volume and bicarbonate secretion are measured (secretin-test). Following the i.v. 
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administration of CCK, the duodenal output of pancreatic enzymes (such as amylase, trypsin, 





Table 2: Overview of direct and indirect pancreatic functions tests. Advantages, disadvantages and 
clinical indications are noted.  
From: Sleisenger and Fordtran's Gastrointestinal and Liver Disease 11th edition 2020. With 
permission from Elsevier.  
 
The advantage of direct tests is that direct quantification of pancreatic secretion is possible. A 
disadvantage is the invasiveness of this test and the lack of commercially available CCK and 
secretin. Even mild and moderate reductions of stimulated pancreatic secretion can be 
detected by this test.  
The Lundh test is an indirect pancreatic secretory function test that requires duodenal 
intubation. This test can be performed when secretin or CCK is not available for direct testing 
as pancreatic secretion is stimulated by a test meal. Duodenal placement of a catheter is still 
required for aspiration of the pancreatic secrete at different time intervals.  
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Other indirect tests are non-invasive and involve measuring fecal fat, fecal chymotrypsin of 
fecal elastase.  
Measuring fecal fat is a cumbersome method. Patients have to follow a strictly defined diet 
when collecting all stool samples for 72 hours. The test is excellent to detect steatorrhea and 
severe pancreatic insufficiency.  
The PABA test was formerly used and after ingestion of N-benzoyl-tryosyl para-
aminobenzoic acid (NBT-PABA), PABA can be quantified in the urine. This test is rarely 
performed nowadays and detects severe pancreatic insufficiency. (5) 
The most-widely used test is the fecal elastase test which indicates significantly decreased 
pancreatic function and which will be explained in the following in more detail.  
 
Quantifying fecal elastase-1 (FE-1) by enzyme-linked immunosorbent assay is currently the 
most widespread screening test for diagnosing exocrine pancreatic insufficiency (Figure 5). 
In contrast to other pancreatic enzymes is elastase-1 highly stable and is not degraded during 
the gastrointestinal passage. Generally, a FE-1 concentration below 200 μg/g feces is 
considered as pathological and compatible with PEI. It is of note, there is disagreement 
among experts about which FE-1 concentration can be used as a cut-off to diagnose PEI and 
there are studies suggesting that FE-1 as low as 15 μg/g feces indicates PEI with sufficient 
certainty. (6) Others have shown that low FE-1 concentrations can provide a false-positive 
and wrongly indicate PEI in patients with watery diarrhea. These are some of the reasons that 
more sensitive methods are needed to diagnose PEI and that additional tests are required to 
interpret mildly reduced FE-1 levels 100-200 μg/g. (7-9) 
 
Figure 5. The fecal elastase-1 ELISA test.  
From https://www.schebo.com/products/pancreatic-elastase-1/. With permission from ScheBo 
Pancreatic elastase-1 stool test, Biotech AG, Giessen, Germany. 
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According to EU guidelines the 13C-mixed triglycerides (13C-MTG) breath test is an 
alternative for the elastase-1 test (Figure 6).   
Vantrappen et al. introduced the 13C-mixed triglycerides (13C-MTG) breath test which is 
regarded to be more sensitive than FE-1 testing and which specifically detects maldigestion of 
triglycerides (10). The subjects receive a test meal consisting of bread, butter and 13C-marked 
triglycerides (2-octanoyl (1-13C)-1,3 distearoyl glycerol) which is a non-radioactive test 
substance.  
In the presence of lipase in the GI tract, triglycerides are metabolized, and 13C-fatty acids are 
subsequently metabolized in the liver to 13CO2. The concentration of 
13CO2 can be measured 
at different points in time the exhaled air and correlates directly with the lipase activity. 13C-
MTG breath test detects moderate pancreatic exocrine insufficiency noninvasively and 
reliably. A disadvantage of this test is that it requires prolonged breath sampling (up to 6 
hours). Shortening of the 13C -MTG test from 6 to 4 hours of duration was shown to have 
similar diagnostic accuracy which increased clinical usability. (10, 11) 
 
Figure 6. In order to calculate the 13CO2/
12CO2 isotope ratios in exhaled breath samples infrared 





1.3 Pathophysiology and etiology of chronic pancreatitis 
Chronic pancreatitis (CP) is a chronic inflammatory disease of the pancreas with an 
inflammatory destruction of the parenchyma leading to fibrosis, atrophy and loss of pancreatic 
function resulting in exocrine and in the later course endocrine insufficiency. The initial steps 
of chronic pancreatitis are intrapancreatic enzyme activation and acute inflammation. Chronic 
inflammation with acute exacerbations of pancreatitis ultimately results in severe 
morphological changes with calcifications, atrophy and changes of the pancreatic duct system. 
Chronic pancreatitis is a rather rare disease with a prevalence rate of 15.5-52.4 cases per 
100,000 inhabitants and an incidence rate around 5 per 100,000 inhabitants per year. (12, 13) 
Diagnosing early CP with nonspecific symptoms and lack of marked pancreatic morphologic 
changes is a challenge and is one of the reasons that CP may be underdiagnosed. 
Alcohol and smoking are still the most important etiological factors for chronic pancreatitis, 
although smoking and alcohol overconsumption is decreasing in many Western countries. All 
main etiologies are summarized in the M-ANNHEIM classification (alcohol consumption, 
nicotine, nutritional factors), hereditary (mutations in PRSS1, CFTR, SPINK1, CTRC genes), 
ductal obstruction and autoimmune factors. (14, 15) Importantly, patients may have a 
combination of different risk factors resulting in a more rapid progression (e.g. smoking and 
alcohol and mutations in risk genes).  
The key pathophysiological steps vary according to the underlying etiology. In alcoholic 
pancreatitis, acetaldehyde has direct toxic effects on acinar cells triggering inflammation with 
subsequent necrosis and apoptosis. Moreover, acetaldehyde activates pancreatic stellate cells 
(PSC) which produce large amounts of extracellular matrix proteins including collagen. Apart 
from oxidative stress, non-oxidative metabolites (fatty acid ethyl ester/FAEE) contribute to 
pancreatic injury. (16) 
1.4 Diagnosis and management of chronic pancreatitis 
 
Diagnosis of chronic pancreatitis is frequently based on imaging. Endoscopic ultrasound 
(EUS), contrast-enhanced computed tomography (CT), magnetic resonance imaging (MRI) 
have the highest sensitivity rates and are the recommended imaging modalities to diagnose 
chronic pancreatitis. (17) EUS is regarded as having the highest sensitivity to diagnose CP 
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and the Rosemont classification was developed to define morphological changes of probable 
and definite CP. (18-21) 
EUS enables the assessment of the pancreas with elastography and can even be used to 
acquire biopsies of the pancreas (EUS-FNB).(22) 
CT is an excellent tool for the detection of pancreatic calcifications whereas MRCP enables 
the characterization of both the parenchyma and the pancreatic duct system with high 
resolution. Endoscopic retrograde cholangiopancreatography (ERCP) was the gold-standard 
to diagnose chronic pancreatitis for decades but is no longer used for mere diagnostic 
purposes due to risk for post-ERCP pancreatitis (PEP).   
The main symptom of chronic pancreatitis is abdominal pain that can be challenging to treat 
successfully and is significantly affecting the quality of life in this patient group. In patients 
with stones in pancreatic duct and abdominal pain, endoscopic stone removal with baskets 
with or without extracorporeal shockwave lithotripsy (ESWL) can be performed. Surgical 
resection should be considered in patients with chronic pain that is not responding to therapy. 
CP patients have a high risk for malnutrition which can be attributed to ongoing alcohol 
misuse, nausea and obstipation due to chronic opioid medications, stenotic complications in 
the gastrointestinal tract due to mass forming CP or due to exocrine pancreatic insufficiency 
with maldigestion and malabsorption. All patients with CP should be screened for 
malnutrition and PEI according to the EU CP guideline. (17) 
 
1.5 Pathophysiology and etiology of pancreatic exocrine insufficiency (PEI) 
 
Pancreatic exocrine insufficiency (PEI) is defined as markedly reduced activity of pancreatic 
enzymes in the intestinal lumen resulting in maldigestion. The pancreas has a very high 
reserve capacity and enzyme activity has to be reduced by 90% until steatorrhea occurs. (23) 
 
This implies that minor reductions of enzyme activity do frequently not result in maldigestion 
and thus are clinically not relevant. These minor reductions are also termed as pancreatic 
dysfunction.  
PEI with maldigestion has a large range of etiologies and pancreatic and non-pancreatic 




Figure 7. Different causes of pancreatic exocrine insufficiency (PEI).  
From: Lindkvist B. Diagnosis and treatment of pancreatic exocrine insufficiency. World J 
Gastroenterol. 2013 Nov 14;19(42):7258-66. With permission from Baishideng Publishing Group Inc. 
 
Chronic pancreatitis with atrophy and loss of functional parenchyma is the most frequent 
cause of PEI. In addition, impaired bicarbonate secretion in CP blunts buffering of gastric 
acids in the duodenum and reduces lipase activity. In constrast, Zollinger-Ellison syndrome 
with high acid concentrations in the duodenum with resulting inactivation of pancreatic 
enzymes is a very rare etiology of PEI. (24-26) 
Other causes of PEI are cystic fibrosis with severe pancreatic atrophy due to CFTR mutations 
and pancreatic resections (e.g. Whipple operation or total pancreatectomy). Benign and 
malignant pancreatic duct obstructions can impair the excretion of pancreatic enzymes leading 
to PEI (Figure 7). All patients with pancreatic cancer should be treated with PERT according 
to current guidelines. Even acute pancreatitis can result in a temporary och persistent 
reduction of pancreatic enzymes. (27) 
According to a meta-analysis, the prevalence of PEI was 62% during hospitalisation and 35% 
during follow-up.  
After GI-surgery including bariatric surgery an increased prevalence of PEI was observed 
(Figure 8). Impaired mixing of pancreatic enzymes with ingested food (postcibal 
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asynchrony), impaired hormonal and neural stimulation of pancreatic secretion contribute to 




Figure 8. Pathophysiology of PEI in common GI surgeries. Decreased hormonal and neural 
stimulation of pancreatic secretion, loss of pancreatic tissue and impaired mixing of food and 
pancreatic enzymes (postcibal asynchrony) are contributing factors of PEI.   
From: Chaudhary A et al. Dig Dis. 2020;38(1):53-68. With permission from Karger AG. 
 
Impaired CCK and secretin production with resultant diminished stimulation of pancreatic 
secretion is even suggested in patients with active celiac disease. (28, 29) 
 
Atrophy of the pancreas can be observed in patients with chronic pancreatitis but atrophic 
changes can also be found in patients with type I diabetes mellitus and subjects of old age 
resulting in PEI. (30, 31) 
There is even evidence that patients with IBD or Sjögren´s syndrome have an increased risk 
of developing pancreatic exocrine insufficiency. (32, 33) 
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1.6 Treatment of PEI 
Treatment of PEI is mandatory and a Spanish study has shown that PEI is associated with an 
increased mortality (hazard ratio 2.59, 95% CI 1.42–4.71). (34) A meta-analysis has shown 
that oral supplementation of pancreas enzymes (PERT) improves nutritional status and 
relieves PEI-related symptoms. Altogether 17 studies with 511 patients were analyzed. PERT 
improved gastrointestinal symptoms and reduced abdominal pain, reduced fecal fat and 
normalized nutritional parameters.(35) 
 
There is accumulating evidence that enzyme replacement therapy is important to treat the 
deficiencies of micro- and macronutrients and thus to decrease the associated risks like 
osteoporosis even if patients do not have characteristic PEI-related symptoms like steatorrhea. 
(23, 36, 37) 
Enteric-coated mini-microspheres are used for oral pancreatic enzyme replacement therapy 
(PERT). Pancreatic enzyme preparations are extracted from porcine pancreata. Per meal 
40,000-50,000 lipase units of microencapsulated pancreatic enzymes are recommended and 
20000-25000 lipase units with every snack. In compliant non-responders the dose can be 
doubled, or proton-pump inhibitors added. If this strategy does not resolve symptoms other 
possible underlying diseases should be ruled out. A treatment algorithm was recently 
published (17).  
1.7 Complications of pancreatic exocrine insufficiency 
 
Symptoms of PEI encompass diarrhea with fatty stools, bloating, abdominal pain, 
malabsorption with reduced calorie intake, deficiencies in micronutrients (calcium, zinc and 
selenium) and fat-soluble vitamins. (38) 
The pancreas as a central digestive gland can be the cause for malabsorption due to pancreatic 
diseases as a chronic inflammation. From the functional point of view, pancreatic bicarbonate 
secretion is most important for duodenal neutralization of gastric acid to enable pancreatic 
enzymes to work optimally. PEI is defined as a critically reduced intestinal pancreatic enzyme 
activity resulting in steatorrhea, bloating, abdominal discomfort, weight loss, and 




Deficiency of fat- soluble vitamins (A, D, E and K) and micronutrients (zinc, magnesium, 
calcium, thiamine and folic acid) have been demonstrated in patients with CP. (33-37) As the 
risk of mortality in patients with CP is related mainly to extra-pancreatic causes, such as 
cardiovascular and respiratory disorders and infections and all these events might be 
worsened by fat-soluble vitamins deficiencies, malnutrition and vitamin deficiency should be 
carefully considered during the management of CP patients. (39-41) 
 
Osteoporosis is defined as a systemic bone disease characterised by low bone density and 
deterioration of bone tissue, with a subsequently increased bone fragility resulting in an 
increased risk for fractures (Figure 9). Dual-energy X-ray absorptiometry (DXA) is the gold 
standard technique for measuring bone mass. Measurements are usually performed at the 
femoral neck and lumbar spine. Bone mass measurements are recorded as Z score, reflecting 
the number of standard deviations (SDs) above or below the mean for an age-matched 
population (in patients < 50 years of age), or T score, reflecting the number of SDs above or 
below the mean for a young adult population (in patients > 50 years of age and 
postmenopausal women). (42) 
Several disorders and diseases such as hyperparathyroidism, hyperthyroidism, chronic renal 
failure, chronic liver disease, gastrointestinal disease and drugs (e.g. glucocorticoids, 
anticoagulants) were shown to be linked to increased bone loss. Low bone mineral density 
(BMD) is a common metabolic finding in chronic intestinal disorders associated with 
diarrhoea and malabsorption and it is also frequent in patients with chronic pancreatitis due to 





Figure 9. Osteoporosis. Dual-energy X-ray absorptiometry (DXA) is the gold standard technique for 
measuring bone mass. Measurements are usually obtained at the femoral neck and lumbar spine. 
Blausen Medical. Retrieved on 25 January 2016. Wikimedia Foundation. Creative Commons CC BY. 
 
 
1.8 IBD and chronic pancreatitis and exocrine pancreatic insufficiency 
 
Inflammatory bowel diseases (IBD) are chronic inflammatory disorders of the gastrointestinal 
tract encompassing Crohn's disease (CD) and ulcerative colitis (UC). The underlying etiology 
of the disease involves a combination of genetic, environmental, immunological and gut 
microbial factors. (46) Mucosal inflammation with diarrhea is characteristic for IBD and is 
present in approximately 80% of patients. (47) 
Pancreatic disorders and abnormalities are not uncommon in IBD. They represent a 
heterogeneous group of pancreatic manifestations that includes acute pancreatitis (AP), 
autoimmune pancreatitis (AIP), chronic pancreatitis (CP), imaging abnormalities and 
asymptomatic elevation of pancreatic enzymes. (48, 49) 
In IBD patients most cases of CP are “idiopathic” which can be considered as extraintestinal 
manifestations of IBD. (50, 51) Other causes are biliary stones or anti-inflammatory drugs 
used for treating IBD.  
Pancreatitis and IBD may have similar clinical signs making it more difficult to make the 
correct diagnosis in patients with ulcerative colitis and Crohn’s disease. However, elevation 
of pancreatic enzymes without clinical symptoms and without morphological signs of 
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pancreatitis should not be considered as pancreatitis. Therefore, only follow-up of pancreatic 
enzymes is recommended. On the other hand, IBD patients with two of three symptoms of 
acute pancreatitis (elevantion of pancreatic enzymes/morphological changes compatible with 
pancreatitis/abdominal pain) should be further investigated and treated. (52, 53) 
Chronic pancreatitis associated with UC differs from that observed in CD by the presence of 
more frequent bile duct involvement, weight loss, and pancreatic duct stenosis. (54) 
Pancreatic involvement in CD can be caused by changes in main pancreatic duct, decreased of 
hormonal signaling due to mucosal inflammation and as a part of autoimmune extraintestinal 
manifestations. (52) 
 
IBD-related CP appears to have different phenotype compared to alcohol-related chronic 
pancreatitis with calcifications. Typically, pseudocysts and pancreatic calcifications are more 
frequently observed in alcohol-related CP compared to IBD-related CP. (52, 53) 
 
1.9 Sjögren’s syndrome and pancreatic exocrine insufficiency  
Sjögren’s syndrome (SS) has been defined as an autoimmune disorder characterized by 
lymphocytic infiltration of salivary and lacrimal glands, leading to dry mouth (xerostomia) 
and eye dryness (keratoconjunctivitis sicca). Moreover, a third of the patients with this disease 
develop several systemic complications, such as renal, pulmonary or neurological 
manifestations (Figure 10). Around 5% of patients with primary SS will develop B-cell 
lymphoma, which are characteristically found in the most affected organs (e.g. salivary 
glands). (55) SS can be seen alone (primary SS) or in association with other connective tissue 
diseases. (56) The estimated prevalence of primary Sjögren's syndrome (pSS) is about 0.2% in 
the adult population and a yearly incidence of 4/100.000. The reported male/female ratio lies 
in the range of 1:9 with an onset age of approximately 45 years. (57) 
Both the pancreas and salivary glands share important functional and histological similarities. 
Both produce bicarbonate-rich fluid with digestive enzymes which are secreted into the 
gastrointestinal tract. Isolated cases of SS in combination with pancreatic calcifications, 
pancreatic autoantibodies and increased pancreatic enzyme levels have been described in 
previous studies. (58-61) Pancreatic dysfunction in SS has been hypothesized, but is still a 
matter of debate. (62) 
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Pancreatic exocrine insufficiency has been also estimated using the N-benzoyl-L-tyrosyl para-
amino-benzoic acid test (NBT-PABA test) and by measuring the trypsinemia by radio-
immunoassay in SS. The NBT-PABA test was pathological in 37.5% of SS but in none of the 
controls and importantly paitients were asymptomatic. Trypsinemia was found to be high in 
6.2% of SS. (63) In a similar study PEI was found in 63% of patients. (64)  
Afzelius et al examined the morphology, the exocrine and endocrine functions of the pancreas 
in SS, but without known pancreatic disease, using secretin-stimulated magnetic resonance 
cholangiopancreatography (MRCP), a Lundh test, oral glucose tolerance test, and blood 

















Figure 10. Systemic 
manifestations of primary 
Sjögren’s syndrome. 
The percentages of patients with 
the various manifestations of 
primary Sjögren’s syndrome were 
derived from reports in the 
Sjögren Big Data project,4 which 
includes information on more 
than 10,000 patients with primary 
Sjögren’s syndrome from 22 
countries.  
From: Mariette X, Criswell LA. 
Primary Sjögren's Syndrome. N 
Engl J Med. 2018;378(10):931-





The overall aims of this study were to provide a better definition of the risk for complications 
of pancreatic exocrine insufficiency in patients with chronic pancreatitis and to further 
elucidate whether diseases such as Crohn's disease and Sjögren´s syndrome are associated 
with pancreatic exocrine insufficiency. 
 
The specific aims of this study were: 
 
Aim I: To evaluate the prevalence of deficiencies of fat-soluble vitamins in patients with 
chronic pancreatitis by applying a systematic meta-analysis. 
 
Aim II: To evaluate the prevalence of osteopenia and osteoporosis in patients with chronic 
pancreatitis and to investigate if vitamin D, CP features and pancreatic exocrine insufficiency 
(PEI) are risk factors for osteopathy in patients with chronic pancreatitis. 
 
Aim III: To evaluate the prevalence of PEI in patients with Crohn's disease (CD). 
 
Aim IV: To evaluate the prevalence of PEI and gastrointestinal symptoms in patients with 





3.1.  Paper I 
 
3.1.1 Study design  
The study was planned and designed by candidates of a European postgraduate program 
(Pancreas 2000: https://www.pancreas2000.org/) with members from six different countries, 
namely Estonia, Germany, Italy, Poland, Spain, Sweden.  
 
The protocol followed the guidelines according to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement and the study was registered in 
the Prospero database (www.crd.york.ac.uk/PROSPERO/). (66)  
 
All studies including specific search terms (such as vitamin A, D, E, K and CP, PEI) were 
retrieved by MEDLINE. Studies from October 1982 until October 2015 were included. Three 
reviewers selected independently all studies meeting the inclusion criteria. All data was saved 
in Microsoft Excel sheets and incongruencies were discussed with a fourth reviewer.  
 
3.1.2 Inclusion and exclusion criteria 
The following criteria were used for inclusion: patients with a diagnosis of CP and > 18 years 
of age, inclusion of at least one of the four fat-soluble vitamins, either a cross-sectional or 
case-control study design and only full papers in English language.  
Case reports or small (<10 patients) case series or publications including patients with other 
gastrointestinal disease-causing malabsorption were excluded. 
 
3.1.3 Study extraction and quality assessment 
After the selection of studies, the following clinical data were extracted: study setting, study 
design, year of publication, number of patients, gender, age, study period, rate of deficiency 
of fat-soluble vitamins and normal values, CP characteristics, prevalence of PEI, diabetes and 
treatment of PEI and source of controls. The quality of the studies was assessed according to 




NOS serves also as a tool to determine the risk for bias in observational studies and is 
recommended by the Cochrane Collaboration. (68, 69) 
 
3.2 Paper II 
 
3.2.1 Patients and study design 
This multicenter cross-sectional study included patients with chronic pancreatitis from seven 
European countries (Estonia, Germany, Italy, Poland, Spain, Sweden and the United 
Kingdom) respectively. Patients were recruited from April 2015 to October 2016. The study 
was developed from members of an European pancreatology postgraduate program (Pancreas 
2000; https://www.pancreas2000.org/). 
 
3.2.2 Inclusion and exclusion criteria 
The following inclusion criteria were applied: age >18 and a diagnosis of chronic pancreatitis 
according to the M-ANNHEIM criteria. (14) The M-ANNHEIM classification of chronic 
pancreatitis enables classification of patients according to etiology and severity of CP. The 
classification is well-established, frequently applied and  recommended by a a recent 
European CP guideline. (15, 17) 
The following exclusion criteria were used: patients with a diagnosis of pancreatic cancer, 
liver cirrhosis, chronic renal failure, primary hyperparathyroidism, celiac disease, IBD and 
previous GI surgery.  
3.2.3 Questionnaire 
A standardized questionnaire based on the local language of the respective country was used to 
evaluate a large range of parameters comprising epidemiological data, current drug 
medication, risk factors for osteopathy, diet, lifestyle factors, past medical history including 
previous fractures. 
 
3.2.4 Dual energy x-ray absorptiometry (DXA) 
Bone mineral density (BMD) of the lumbar spine and of the left femoral neck was assessed by 
standardized osteodensitometry applying dual energy x-ray absorptiometry (DXA). Results of 
bone mass measurements were recorded and summarized by T-scores, that reflect the number 
of standard deviations above or below the mean for a young adult population. Osteopenia is 
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defined as a T-score < -1 and osteoporosis is defined as a T-score < -2.5. DXA examinations 
were performed at each participating centre not later than 6 months from the time of 
enrolment. DXA was performed at the Department for Endocrinology at Karolinska University 
Hospital, Huddinge. 
 
3.2.5 Laboratory testing 
All studied laboratory parameters - apart from vitamin K -  were determined at the local study 
centers. These parameters were: vitamin D, albumin, total and ionized calcium, magnesium, 
parathormone (PTH), triglycerides, cholesterol, transferrin, hemoglobin, mean corpuscular 
volume (MCV), lymphocytes, vitamin B12, folic acid, prothrombin time, INR and partial 
thromboplastin time.  
Vitamin K levels were quantified at the laboratory of S. Andrea Hospital, University 
“Sapienza” Rome, Italy for standardized measurements. Blood from patients of all centers was 
drawn, immediately thereafter centrifuged and frozen at – 80°C. Finally, frozen samples were 
shipped to Rome for vitamin K analysis by high performance liquid chromatography (HPLC). 
 
The presence of PEI was investigated by a faecal elastase-1 test. A monoclonal enzyme-linked 
immunosorbent assay was used to investigate faecal elastase-1 levels (ScheBo Pancreatic 
elastase-1 stool test, Biotech AG, Giessen, Germany). Results were defined as normal 
pancreatic function (> 200 mcg/g of stool), mild pancreatic exocrine insufficiency (100 - 200 
mcg/g of stool) and severe pancreatic exocrine insufficiency (< 100 mcg/g of stool). 
 
3.3 Paper III  
 
3.3.1 Patients and study design 
A monocenter cross-sectional pilot study on CD patients who were recruited at the 
Department for Gastroenterology at Karolinska University Hospital in Stockholm, Sweden. 
Data as gender, age, duration of CD and its treatment, smoking, and stool assessment by 




3.3.2 Inclusion and exclusion criteria 
Inclusion criteria was: age >18 and a diagnosis of CD. Exclusion criteria were the following: 
participants who signed informed consent but could not perform FE-1 and participants who 
could not speak either Swedish or English.  
 
3.3.3 Laboratory testing 
PEI was estimated with faecal elastase-1, measured using a monoclonal enzyme-linked 
immunosorbent assay. Results were classified as normal pancreatic function (more than 200 
mcg/g of stool), mild pancreatic exocrine insufficiency (100 to 200 mcg/g of stool) and severe 
pancreatic exocrine insufficiency (less than 100 mcg/g of stool).(7) Retrospectively we 
assessed a Calprotectin. (80) Calprotectin is a fecal marker that grades the lever of CD 
inflammation by measuring a protein released in stool. A normal value is considered by less 
than 50 μg/g. (71) 
 
3.3.4 Endoscopic activity scores in patients with Crohn´s disease 
Recent colonoscopy examinations were retrospectively assessed to rule out active 
inflammatory bowel disease in the colon. (70, 72) Activity was classified according to the 
Simple Endoscopic Score of CD (SES-CD) and the Rutgers’s Score (RS) in patients after 
ileocecal resection, respectively. (69, 72, 73) The SES-CD is a simple and 
validated endoscopic score for describing ileocolonoscopy findings in CD using parameters 
(ulcer size, ulcerated surfaces and narrowing) scored at each colonic segment from 0 to 
3. (73)  
The RS scoring includes lesions from the bowel segment: i0: no lesions; i1: < 5 aphthous 
lesions; i2: > or equal to 5 aphthous lesions with normal mucosa between lesions or skip areas 
of larger lesions or lesions; i3: diffuse aphthous ileitis with diffusely inflamed mucosa and i4: 
diffuse inflammation with larger ulcers, nodules and/or narrowing. (72) 
 
3.4 Paper IV 
 
3.4.1 Patients and study design 
A monocenter cross-sectional pilot study on SS patients who were recruited from the 
Department for Rheumatology at Karolinska University Hospital in Stockholm, Sweden. Data 
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as gender, age, duration of SS, lip biopsies and presence of anti-SSA autoantibodies were 
analyzed.  
 
3.4.2 Inclusion and exclusion criteria 
All male and female patients with primary SS, and all patients older than 18 years of age or 
younger than 75 years of age were included into the study. The following patients were 
excluded: patients with secondary SS and all SS patients <18 years of age or > 75 years of 
age. In addition, all patients with a known pancreatic disease were excluded (e.g. 
acute/chronic pancreatitis, previous pancreatic diagnostic or therapeutic interventions 
including surgery and ERCP). 
 
3.4.3 Evaluation of gastrointestinal symptoms 
To evaluate gastrointestinal symptoms in SS patients we applied the Gastrointestinal 
Symptom Rating Scale (GSRS), which represents a reliable, and strictly validated 
questionnaire comprising 15 items with five groups of symptoms comprising reflux, 
abdominal pain, constipation, diarrhea and indigestion. (74-76). Sex and age-matched controls 
were chosen from the previously described PopCol study, which represents a population-
based colonoscopy study. 
We have evaluated gastrointestinal symptoms through an established survey Gastrointestinal 
Symptom Rating Scale (GSRS-IBS). GSRS-IBS contains 13 items which measure severity of 
gastrointestinal symptoms such as abdominal pain, pain relieved by a bowel action, bloating, 
passing gas, constipation, diarrhea, loose stools, hard stools, urgent need for bowel 
movement, incomplete bowel emptying, fullness shortly after meal, fullness long after eating, 
and visible distension. (77) The study was based on a Swedish population sample of 1158 
randomly selected participants provided data on the GSRS-IBS. (78, 79) 
  
3.4.4 13C-mixed triglyceride breath test 
PEI was assessed with a 13C-mixed triglyceride breath test. (13) 13C-MTG breath test was 
performed at Karolinska University Hospital in 21 patients. Results were considered as 
normal in patients with a cumulative 13C exhalation > 20.9% after 5 hours of testing according 
to Keller et al. (11)  
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Our test meal consisted of two slices of white bread, 20 g of butter, and 30 g of chocolate 
cream (Nutella; Ferrero, Germany). The latter was carefully mixed with 200 mg of 13C-MTG 
(13C- MTG: [2-octanoyl(1-13C)-1,3 distearoyl glycerol]; Euriso-Top, catalogue number 
INC650P, triglyceride with 13C-octanoic acid [labelled with 1 13C-atom] bound to the Sn-2 
position and unmarked long-chain fatty acids bound to Sn-1 and Sn-3 positions).  
The meal was ingested together with 200 mL of water within 10 minutes. The total caloric 
value was 420 kcal (1770 kJ). Breath samples were taken before the ingestion of the test meal 
and every 30 minutes for 5 hours thereafter. No physical activity was allowed throughout the 
test. The 13CO2/
12CO2 isotope ratio in breath was determined using isotope-selective non- 
dispersive infrared spectrometry (IRIS-3; Wagner Analysen Technik GmbH, Bremen 
Germany/Kibion Uppsala/Sweden).
 
The results were analyzed as % values and expressed as a 
maximal or cumulative percentage of dose of 13C recovered over 1- to 5-hour intervals.  
 
3.4.5 Laboratory testing 
PEI was estimated with faecal elastase-1, measured using a monoclonal enzyme-linked 
immunosorbent assay. Results were classified as normal pancreatic function (more than 200 
mcg/g of stool), mild pancreatic exocrine insufficiency (100 to 200 mcg/g of stool) and severe 




3.5 STATISTICAL ANALYSIS 
 
3.5.1 Paper I 
Deficiency rates of all studied fat-soluble vitamins were pooled on the basis of all included 
studies (cohort studies and case-control studies). For case-control studies, deficiency rates in 
CP patients and controls were separately pooled, and the individual relative odds ratio (OR) 
and 95% confidence interval (CI) calculated.  
The software package Comprehensive Meta-Analysis (Biostat, Englewood, NJ, USA) was 
used for all statistical calculations. The quantity of heterogeneity was assessed by means of 
the I2 values. (80) We considered an I2 value of 25% or lower as low heterogeneity, and an I2 
value of 75% or higher as considerable heterogeneity.  
The Begg and Mazumdar test was used to assess publication bias. A p-value < 0.05 regarded 
as statistically significant. 
 
3.5.2 Paper II 
Fisher exact test was used for analyzing categorical variables and t-test for continuous 
variables.  
A univariate and a multivariate logistic regression analysis was performed to identify 
nutritional and clinical parameters that were correlated with BMD. For every parameter the 
odds ratio (OR) and the respective 95% confidence interval (CI) was calculated. The possible 
correlation between continuous variables was assessed by a Pearson correlation test. All p-
values were two-sided and a p-value < 0.05 were regarded as statistically significant. All 
statistical analyses were carried out by MedCalc version 13 (MedCalc Software, Belgium). 
  
3.5.3 Paper III 
Standard methods for descriptive statistics were used. Categorical variables were presented as 
frequencies (n) and percentages (%). Continuous variables were presented by median and 
range.  
 
3.5.4 Paper IV 
Descriptive statistics were used to summarize patient demographics (gender, age), disease 
characteristics (duration of SS, lip biopsy findings and presence of autoantibodies), and 
outcomes. Categorical variables are presented by frequency (N) and percentages (%). The 
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differences between those with Sjögren´s syndrome and those without were evaluated by chi-
square tests for these variables. Mean ± standard deviation (SD) or median (interquartile range) 
was used to illustrate continuous variables. T tests were used to estimate the variations for such 
factors.  
Moreover, we performed a propensity score-matched analysis to create comparable risk 
groups with respect to 11 different items of GI symptoms in SS patients and sex and age-
matched controls from the PopCol study. Matching was achieved using propensity scores, 
which represent the probability of group assignment conditional on observed baseline 
covariates. (81) Matching pairs were formed in a manner to ensure that matched subjects had 
similar values of the propensity scores i.e. for a patient with Sjögren´s syndrome. All the 
control subjects whose propensity score lay within a specified distance (caliper distance) were 
identified. A smaller distance ensures a better chance to have similar groups with respect to 
the set of covariates, and thus we chose a caliper distance of 0.0001. Participants with 
propensity scores outside the specified caliper distance of the propensity score were removed 
from the matching sample. Participants were matched for any significant differences seen 
between the two groups with respect to age and gender. Standardized differences were 
calculated to compare patient features before and after matching with imbalance being 
defined as an absolute value greater than 0.10 (small effect size). (81)  
Matching was performed using the nearest neighbor algorithm based on a four-digit match of 
the propensity score. This strategy allowed the inclusion of comparable cohorts with respect 
to different items of GI symptoms. Statistical analyses were performed in R Statistical 
software version 3.6.3 (R Foundation for Statistical Computing, Vienna, Austria) using the 
package MatchIt. 
Univariate Logistic Regression Analysis: After propensity score matching, we then conducted 
univariate logistic regression analyses. 
 
3.6 ETHICAL CONSIDERATIONS  
 
For the first study we did not need ethical approval because it was meta-analysis. The second, 
third and fourth studies were approved by the Regional Review Board, Stockholm, Sweden. 
(EPN Dnr :2016/491-31/2 and Dnr: 2017/650-31/4) Oral and written informed consent was 





4.1 Paper I 
 
Initially, 381 potential studies were retrieved from PUBMED and ultimately 12 articles with 
altogether 548 patients with chronic pancreatitis met the inclusion criteria for further meta-
analysis. Five cross-sectional studies and seven case-control studies were included for further 
analysis that were published from October 1982 until October 2015 (Figure 11). 
 
The overall rate of deficiencies for vitamin D, E and A were 57.6% (95% CI, 43.9-70.4), 
29.2% (95% CI, 8.6-64.5) and 16.8% (95% CI, 6.9-35.7), respectively.  




Figure 11. The selection process of suitable publications is illustrated as a PRISMA diagram 
(http://www.prisma-statement.org/). 
The large majority of the included studies were conducted in Europe (7/12), two studies were 
from India and only one study from each of the following countries: South Africa, Argentina, 
and the US, respectively.  
Alcohol was the most frequent etiology for chronic pancreatitis, followed by idiopathic 
chronic pancreatitis. Two studies did not note the etiologic factor.  
The prevalence of PEI had a high variation ranging from 35% to 100%. In parallel, rates of 




Results of the meta-analysis are illustrated as forest plots.  
 
 
Figure 12. The pooled prevalence vitamin A deficiency in chronic pancreatitis was 16.8% (95% CI, 
6.9%-35.7).  
Four studies (40, 82-84) with altogether 161 patients were included in this analysis and 
showed a pooled prevalence rate of 16.8% for Vitamin A deficiency in 161 patients with 
chronic pancreatitis. When two studies with lower quality was excluded the pooled prevalence 
rate was 7.7% (95% CI 1.4-33.5). Of note, a considerable heterogeneity between the studies 




Figure 13. The pooled prevalence of vitamin E deficiency in chronic pancreatitis was 29.2% (95% CI, 
8.6%-64.5).  
 
This calculation was based on four studies (40, 45, 83, 84) including 161 patients. A 
publication bias was ruled out by testing according to Begg and Mazudmar. Heterogeneity 
was considerable (I2=92%). 
The prevalence of vitamin E deficiency was much lower, when only the two high quality 





Figure 14. The pooled prevalence of vitamin D deficiency in chronic pancreatitis was 57.6% (95% CI, 
43.9-70.1).  
Eleven studies with 504 CP patients were included. The pooled prevalence of deficiency was 
57.6% (95% CI, 43.9-70.4%) (Figure 14). Different definitions of vitamin D deficiency 
according to different cut-off values were taken into account. Vitamin D < 20 ng/ml was 
regarded as deficiency. 
Studies with high rates of PEI (>70%) (40, 43, 84, 85) were compared with studies with lower 
rates of PEI. (94-96) Interestingly, studies with high rates of PEI demonstrated only a minor 
increase in the rate of vitamin D insufficiency.  
Only five studies (82, 85-88) were available to compare the prevalence of vitamin D 
deficiency in patients with chronic pancreatitis versus control. No statistical difference was 
found (OR 1.17; 95% CI, 0.77-1.78; p=0.46). 
 
4.2 Paper II 
 
Altogether, 211 patients with CP were included in study. Roughly two-thirds of patients 
(67%)  were male and the mean of age of the cohort was 60 years. Alcohol was the etiology in 
43.6% of cases representing the main etiology of CP in this cohort.  
More than two-thirds (69%; 145/211) had a history of smoking and 70% of them were 
considered as  heavy smokers. Diabetes mellitus was present in 37% (77/211) of cases. The 
mean BMI at the time of enrolment was 24 ± 4. In total, 69 female CP patients were included 
and almost every third female patient (29%) was in menopause.  
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According to the M-ANNHEIM classification, 18% had advanced CP and more than half of 
CP patients (56.42%) had PEI.  
In total, more than half of patients had a vitamin D deficiency (56.4% (115/204)) and almost 
one-third of patients had had vitamin K deficiency (31.5% (56/178)). All patient 
characteristics are summarized in (Table 3).  
 





An univariate and multivariate regression analysis was conducted to identify possible risk 
factors for osteopathy on the basis of all 211 CP patients. Only three parameters were 
identified as potential risk factors both in the univariate and the multivate analysis (Table 4).  
 
 
Table 4: Possible risk factors for osteoporosis identified by multivariate logistic regression 
analysis in all CP patients (n=211). Only statistically significant results are shown. 
  
CP (n=211) OR (95% CI) P-value  
Female sex 
2.78 (1.02–
1.11) 0.001  
Age 
1.07 (1.16–
6.68) 0.021  
BMI  
0.84 (0.74–
0.95) 0.006  
 
Based on both the univariate and multivariate analysis, the following parameters were not 
associated with osteopathy: alcohol as the etiologic factor, smoking, severity of CP, presence 
of PEI, presence of oral enzyme supplementation (PERT), vitamin K and D deficiency. 
 
In a separate Pearson correlation test, no statistically significant correlation between vitamin 
D levels and T-scores could be demonstrated.  
 
A separate univariate and multivariate analysis was conducted to study the correlation of 
vitamin D and K only in male patients. Interestingly, vitamin K deficiency in patients with 
osteoporosis (27.7%) was more frequent compared with those without osteoporosis (5.9%) 
(OR 95% CI, 1.31-21-40; p=0.01).   
 
4.3 Paper III 
 
Twenty patients were included in this study comprising 65% (13/20) males and 35% (7/20) 
females. Mean duration of CD was 15.7 ± 2.1 years. Eleven patients (55%) did not have a 
history of bowel surgery and 9 (45%) patients underwent ileocecal resection. FE-1 was 
normal in all patients. The majority of patients 16 (80%) were non-smokers and alcohol 
overconsumption was not reported. None of the patients had a previous history of pancreatitis. 
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Most patients had an ongoing treatment with one anti-inflammatory drug and the majority of 
patients received oral azathioprine (8/20) (Table 5).  
 
 
Table 5: Demographic and clinical characteristics of all included patients  
 













1 male 60 10 former stool 3x per day 
(Bristol 4-6) 





31 azathioprine >500 
2 male 48 14 never stool 4x per day 
(Bristol 4-6) 
SES-CD:2 20 5-ASA >500 
3 male 45 5 never stool 4x per day 
(Bristol 4-6) 
SES-CD:0 43 azathioprine  >500 
4 male 44 12 former stool 2x per day 
(Bristol 4) 
SES-CD: 0 346 azathioprine >500 
5 female 57 1 never stool 5-7x per 








(status post liver 
transplantation) 
>500 
6 female 57 30 former stool 1-2x per 
day (Bristol 4) 
SES-CD: 0 45 azathioprine and 
5-ASA 
>500 
7 male 48 17 never stool 1-2x per 
day (Bristol 4) 
SES-CD: 0 306 infliximab >500 








16 prednisolone  >500 
9 male 30 5 never stool 2x per day 
(Bristol 6) 
SES-CD: 6 65 azathioprine >500 








123 azathioprine  >500 
11 male 43 17 never stool 2x per day 
(Bristol 4) 
SES-CD: 0 141 azathioprine >500 
12 male 50 40 never stool 4-5 x per 
day (Bristol 6) 








103 5-ASA >500 
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13 female 51 1 former stool 1-6x per 







109 azathioprine  338 
14 female 42 26 never stool 1-2x per 











15 female 67 1 never stool 1-2x per 
day (Bristol 5-6) 
SES-CD: 0 125 no regular 
treatment 
246 
16 male 29 20 never stool 1-2x per 
day (Bristol 4-5) 
SES-CD: 0 41 5-ASA >500 
17 male 56 35 never stool 1x per day 
(Bristol 4-5) 













75 azathioprine >500 
19 male 47 7 never stool 4-5x per 







73 budezonide 411 
20 female 58 10 never stool 2x per day 
(Bristol 5-6) 
SES-CD: 0 67 adalimumab 434 
CD=Crohn’s disease; calpro=calprotectin; FE-1=fecal elastase-1; SES-CD=Simple Endoscopic score of Crohn’s 
Disease; 5-ASA=5-acetyl salicylic acid 
 
4.4 Paper IV 
 
One-hundred-twenty-two patients were contacted by mail and have been invited to participate 
in the study. Altogether, 57 SS patients responded and were included in the study. A 
characteristic feature of primary SS is that primarily females are affected. Consequently, 92 % 
of included patients were females with a median age of 63 years and a median age of 
diagnosis of 52 years (Table 6 and 7). Almost all patients (96%) had undergone lip biopsy 
and 44% had positive SS-A autoantibodies. All patients met the classification criteria of the 
American-European Consensus Group (AECG). (89)  
Fifty of fifty-seven SS patients (87%) provided a fecal sample for FE-1 testing and in all 
tested patients FE-1 was normal. All patients were invited to perform a 13C-MTG breath test 
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and 37% (27/57) of SS patients gave their approval to conduct a breath test which was normal 
in all (data not shown). 
Almost all SS patients responded to the GSRS questionnaire 53/57 (93%). We compared 
results of 42 SS patients with results of 82 sex and age-matched controls stemming from the 
PopCol study and calculated the odds ratios of every item in a univariate logistic regression 
analysis (Table 8). 
A large number of patients noted moderate to severe symptoms such as abdominal pain, 
bloating, diarrhea, loose stools, hard stools, or constipation. Interestingly, symptoms closely 
related to IBS were frequently noted (feeling of incomplete emptying after defecation; relief 
of abdominal pain after bowel movement).   
Based on the univariate logistic regression analysis, the highest odd ratios were noted for the 
following moderate to severe symptoms: bloating (OR: 27.9, 95% CI: 9.81-91.9), feeling of 
incomplete emptied bowel after defecation (OR 21.4, 95%: 6.95-75.8), and abdominal pain 
relieved by bowel action (OR 17.8, 95% CI: 6.04-62.2).   
 
Table 6. Patient characteristics of patients with Sjögren´s syndrome (n=57) 
 
Characteristic N = 571 
 
Age 63 (10) 
Age at diagnosis 52 (11) 
 
Positive biopsy (labial gland) 
yes 50 (96%) 
no 2 (3.8%) 
Positive anti-SSA 
yes 25 (44%) 
no 32 (56%) 
 




Table 7. GI symptoms in Sjögren´s syndrome (n=42) compared to age and sex-matched 










Males 3 (7.1%) 6 (7.3%) 
 
Females 39 (93%) 76 (93%) 
 
Q 1. Abdominal pain  <0.001 
No Symptoms 8 (19%) 47 (57%)  
Minor/mild 12 (29%) 27 (33%) 
 
Moderate to severe 22 (52%) 8 (9.8%) 
 
Q 2. Abdominal pain relieved by bowel action <0.001 
No Symptoms 13 (31%) 58 (71%)  
Minor/mild 9 (21%) 19 (23%) 
 
Moderate to severe 20 (48%) 5 (6.1%) 
 
Q 3. Bloating   <0.001 
No Symptoms 6 (14%) 62 (76%)  
Minor/mild 9 (21%) 10 (12%) 
 
Moderate to severe 27 (64%) 10 (12%) 
 
Q 4. Passing gas  <0.001 
No Symptoms 6 (14%) 37 (45%)  
Minor/mild 13 (31%) 27 (33%) 
 
Moderate to severe 23 (55%) 18 (22%) 
 
Q 5. Constipation  <0.001 
No Symptoms 8 (19%) 57 (70%) 
 
Minor/mild 18 (43%) 12 (15%) 
 
Moderate to severe 16 (38%) 13 (16%) 
 
Q 6. Diarrhea  <0.001 
No Symptoms 23 (55%) 64 (78%) 
 
Minor/mild 6 (14%) 14 (17%) 
 
Moderate to severe 13 (31%) 4 (4.9%) 
 
Q 7. Loose bowel movements <0.001 
No Symptoms 17 (40%) 63 (77%) 
 
Minor/mild 9 (21%) 15 (18%) 
 
Moderate to severe 16 (38%) 4 (4.9%) 
 
Q 8. Hard stools <0.001 
No symptoms 10 (24%) 55 (67%) 
 
Minor/mild 15 (36%) 16 (20%) 
 
Moderate to severe 17 (40%) 11 (13%) 
 
Q 9. Urgent need to have bowel movement <0.001 
No Symptoms 12 (29%) 61 (74%) 
 




Moderate to severe 19 (45%) 8 (9.8%) 
 
Q 10. Feeling of incomplete emptied bowel <0.001 
No Symptoms 8 (19%) 57 (70%) 
 
Minor/Mild 16 (38%) 19 (23%) 
 
Moderate to severe 18 (43%) 6 (7.3%) 
 
Q 11. Fullness after starting meal <0.001 
No Symptoms 18 (43%) 65 (79%) 
 
Minor/Mild 13 (31%) 6 (7.3%) 
 
Moderate to severe 11 (26%) 11 (13%)   
 
 
Table 8. GI symptoms in Sjögren´s patients (n=42) compared to sex- and age-matched 
healthy controls (n=82). Analysis based on univariate logistic regression analysis 
 
Characteristic OR 95% CI p-value 
Q1. Abdominal pain   <0.001 
No symptoms    
Minor/mild  2.61 0.96-7.44  
Moderate to severe 16.2 5.64-52.0  
Q2. Abdominal pain relieved by bowel action <0.001 
No symptoms    
Minor/mild  2.11 0.77-5.71  
Moderate to severe 17.8 6.04-62.2  
Q 3. Bloating   <0.001 
No symptoms    
Minor/mild  9.30 2.79-33.7  
Moderate to severe 27.9 9.81-91.9  
Q 4. Passing gas   <0.001 
No symptoms    
Minor/mild  2.97 1.03-9.38  
Moderate to severe 7.88 2.87-24.5  
Q. 5 Constipation   <0.001 
No symptoms    
Minor/mild  10.7 3.92-31.8  
Moderate to severe 8.77 3.20-26.0  
Q. 6 Diarrhea   <0.001 
No symptoms    
Minor/mild  1.19 0.38-3.37  
Moderate to severe 9.04 2.88-34.7  
Q 7. Loose bowel movements <0.001 
No symptoms    
Minor/mild  2.22 0.81-5.93  
Moderate to severe 14.8 4.75-57.2  
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Q 8. Hard stools   <0.001 
No symptoms    
Minor/mild  5.16 1.98 -14.1  
Moderate to severe 8.50 3.17-24.4  
Q 9. Urgent need to have bowel movement <0.001 
No symptoms    
Minor/mild  4.30 1.56-12.1  
Moderate to severe 12.1 4.47-35.7  
Q 10. Feeling of incomplete emptied bowel <0.001 
No Symptoms    
Minor/Mild  6.00 2.28-17.0  
Moderate to severe 21.4 6.95-75.8  
Q 11. Fullness after starting meals <0.001 
No symptoms    
Minor/mild  7.82 2.71-25.1  







Deficiencies of fat-soluble vitamins are frequent in patients with chronic pancreatitis, but 
there is considerable heterogeneity between different studies. The highest rate for deficiency 
was noted when analyzing vitamin D. Only a few studies compared CP patients to a control 
group and based on these studies no increased risk for vitamin D deficiency was found in CP 
patients.   
 
A high rate of osteopenia and osteoporosis was found in patients with chronic pancreatitis. 
Moreover, high prevalence rates of vitamin D deficiency and pancreatic exocrine 
insufficiency (PEI) were noted that were not correlated with osteopathy. 
Female sex, age and BMI were associated with of osteoporosis in the whole cohort, while in 
male patients, the only risk factor associated with osteoporosis was vitamin K deficiency. 
 
All patients with Crohn's disease with clinical remission that were included in our study had 
normal fecal elastase-1 levels indicating absence of PEI in this group of patients. 
 
Based on our study, the great majority of patients with primary Sjögren´s syndrome suffered 
from IBS-like GI symptoms that cannot be attributed to pancreatic exocrine insufficiency.
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6. GENERAL DISCUSSION 
 
6.1 Paper I 
By a systematic meta-analysis we determined the prevalence of deficiencies of fat-soluble 
vitamins in patients with chronic pancreatitis. Pooled prevalence of fat-soluble vitamins were 
shown to be high for vitamin D, E and E (57.6% and 29.2%, 16.8%, respectively). 
Pancreatic exocrine insufficiency with resulting maldigestion and malabsorption of fat-soluble 
vitamins is a well-defined complication in patients with advanced chronic pancreatitis. (90) In 
spite of this, previous studies published prevalence rates of vitamin deficiencies with large 
variations. To better assess the risk for vitamin deficiencies in CP patients, we performed a 
meta-analysis that strictly followed the recommendations defined by PRISMA.  
 
The strength of the study was that all 12 studies were tested for publication bias via the Begg 
and Mazumdar test and for study quality by applying the Newcastle Ottawa Scale. Moreover, 
heterogeneity of included studies was tested. Testing for heterogeneity is crucial when 
conducting a meta-analysis as it is more difficult to draw conclusions if the included studies 
have a very heterogeneous study design. Noteworthy, the included studies of this meta-
analysis exhibited significant heterogeneity. For example, cut-off values of vitamins varied in 
the studies. 
Three of four fat-soluble vitamins were evaluated in this meta-analysis (vitamin D, E, A). 
Only one single study published results of vitamin K in CP patients and was not included in 
the analysis. Vitamin K is rarely measured in laboratories and INR-levels are serving as a 
substitute parameter which is increased in vitamin K deficiency.  
Two different types of studies were included in this meta-analysis, namely cross-sectional 
studies/cohort studies and case-control studies. Surprisingly, only few case-control studies 
were available for further analysis although they are clearly preferable in order to determine if 
vitamin deficiencies can be attributed to chronic pancreatitis. To answer this question, a 
control group is advantageous. This can be exemplified by the results of vitamin deficiencies. 
In total, 57.6% (95% CI, 43.9-70.4%) of CP patients had vitamin D deficiency which is a 
clearly defined risk factor for osteopathy. Surprisingly, no statistical difference was found 
when comparing significance rates of CP patients with controls. In a recent systematic review 




Different factors can contribute to the fact that no significant difference was observed 
between CP patients and controls:   
CP patients with early stage of chronic pancreatitis do not have developed PEI and 
consequently will not have an increased risk to develop vitamin D deficiency due to 
maldigestion. Not all included studies have clearly indicated the number of patients with 
proven pancreatic exocrine insufficiency.  
Patients with advanced CP and established pancreatic exocrine insufficiency who receive a 
pancreatic enzyme replacement therapy (PERP) will usually no longer have maldigestion with 
impaired absorption of fat-soluble vitamins. This patient group with a proper oral treatment 
will have a similar risk for vitamin deficiency compared to controls. This could even be an 
explanation for the observation that no significant difference was noted when comparing 
vitamin D deficiency in CP patients with PEI versus CP patients without PEI. Interestingly, 
the prevalence of PEI varied significantly from 35 to 100% and in parallel, the percentage of 
patients receiving pancreatic enzyme supplementation varied from 46 to 100% on the basis of 
the included studies, demonstrating significant heterogeneity.   
Meta-regression is another statistical method to address the problem of heterogeneous studies 
in meta-analysis which was not applied in our study. (92) 
To get a better notion of the association of vitamin deficiency and PEI, only CP patients with 
newly diagnosed untreated PEI could be included in a future study. The disadvantage is that it 
would be much more difficult to include a large number of CP patients when applying this 
inclusion criterion. It might be even noteworthy, that the prevalence of vitamin D deficiencies 
are related to sun exposure and geographical areas. Consequently, deficiency rates differ 
significantly within Europe. (91) 
The majority of studies (7/12) were conducted in Europe. It would be interesting to study in 
future studies if there are differences in vitamin deficiencies when comparing data from 
different continents. It has been taken into account that vitamin D deficiency is high in the 
general population and related to sun exposure. According to a study from France, vitamin D 
deficiency was more prevalent in the northern parts of France (93). Vitamin D deficiency is 
regarded as a worldwide problem with high prevalence rates in the population (94). 
A limitation of the included studies is the limited information regarding ongoing alcohol-
consumption in CP patients. Ongoing alcohol misuse is a well-established risk factor for 
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malnutrition and vitamin deficiencies (83). Consequently, the limited number of CP patients 
did not enable an analysis of vitamin deficiencies in relation to different etiologies which 
would clearly be of interest.  
Although studies were tested for selection bias, we have to take into consideration that most 
studies were conducted at university hospitals suggesting the presence of a selection bias. One 
might hypothesize that CP patients at tertiary referral centers have more advanced CP with 
complications. On the other hand, CP patients at tertiary referral centers may have a better 
treated PEI-related maldigestion due to better follow-up and integration in multidisciplinary 
teams with dietitians.  
When performing the meta-analysis only one study analyzed vitamin K levels in CP patients.  
(84) This motivated us to initiate a multicenter study in order to investigate vitamin K in this 
patient group. (95) 
In summary, interesting questions are still unresolved and could be addressed in future 
studies:  
1. How many patients with newly diagnosed untreated PEI have vitamin deficiencies 
compared to controls? 
2. How many CP patients with PEI and ongoing enzyme replacement therapy have 
vitamin deficiencies? Are rates of deficiencies related to the daily oral dose of 
enzymes? 
3. Are deficiency rates in CP patients higher in pateints with more advanced CP? 
4. Is the risk vitamin deficiencies in CP patients dependent on the etiology of CP? 
5. What is the risk for vitamin deficiencies in CP patients with ongoing alcohol misuse 




6.2 Paper II  
In Paper II we conducted a large prospective multicenter study including 211 well-
characterized patients with chronic pancreatitis in order to define the role of osteopathy and 
its risk factors in chronic pancreatitis.  
There is evidence that osteoporosis has a high prevalence in CP with a pooled rate of 23% 
according to a meta-analysis from 2014. (82) The same meta-analysis demonstrated 
heterogeneity of study results with large variations of the prevalence rates of osteoporosis. 
Contributing factors for these variations were small patient numbers in previous studies and 
incomplete data regarding prevalence rates of exocrine pancreatic insufficiency and oral 
enzyme replacement therapy (PERT). 
The pathophysiology of advanced chronic pancreatitis resulting in PEI with subsequent 
maldigestion and malabsorption of fat-soluble vitamins are well-characterized but the specific 
risk factors for osteopathy in chronic pancreatitis are ill-defined.  
Osteopathy results from bone remodelling with increased resorption and resulting low bone 
mineral density and demineralisation. Several factors can contribute to osteoporosis: vitamin 
D and calcium malabsorption, therapy with glucocorticoids, smoking, physical inactivity, 
hormonal imbalances with low estrogen and chronic inflammation including IBD and 
cholestatic liver diseases. (96) 
In the present study, chronic pancreatitis was classified according to the M-ANNHEIM 
classification which systematically assesses the etiology and severity of chronic pancreatitis 
(14) The classification is well-established and was applied in numerous clinical studies. 
Furthermore, the application of this classification is recommended by a recent EU guideline 
on the diagnosis and therapy of chronic pancreatitis. (17)  
Bone density was prospectively examined by dual-energy X-ray absorptiometry which 
represents the gold standard for the diagnosis of osteopenia and osteoporosis. 
Similar to previous studies a high percentage of patients demonstrated vitamin D deficiency 
(56%) and almost one-third patients (32%) had a vitamin K deficiency.  
The strength of the study was that vitamin K was included in the analysis. There is 
accumulating evidence that the fat-soluble vitamin K is involved in bone homeostasis besides 
its contributory role in the production of coagulation factors by posttranslational modification. 
Vitamin K diminishes activity of osteoclasts by gamma-carboxylation of key proteins such as 
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RANK-L and NF-kB (11). It is of importance that vitamin K deficiency was observed in 
patients with pathological fractures, patients with Crohn's disease with osteopathy and cystic 
fibrosis patients. (97-99)  
Vitamin K1 is the main isoform which is termed phylloquinone. The main source of vitamin 
K are green vegetables and fruits. In contrast, vitamin K2 (menaquinone) is produced by 
intracolonic bacterias (microbiome). (100, 101) 
When analyzing the cohort of male CP patients by univariate and multivariate analysis 
vitamin K deficiency was the only risk factor associated with low bone mineral density with a 
high odds ratio of 5.28 (95 CI, 1.31-21-40, p=0.01). This association was not confirmed when 
performing a regression analysis on the basis of the whole cohort of 211 male and female CP 
patients. Here female sex was a significant risk factor for osteoporosis (OR 2.78, CI 95% 
1.16-6.68, p=0.021). All female patients with vitamin K deficiency where shown to be 
postmenopausal - which is known to be correlated with osteoporosis. (102) 
A thorough analysis of all available parameters did not demonstrate an association of vitamin 
D deficiency, PEI, fecal elastase, advanced disease or active smoking with osteoporosis. 
The high rate of vitamin K deficiency in male patients with chronic pancreatitis is an 
important finding and we draw the conclusion that further and even larger prospective studies 
are required to better define the risk factors for osteoporosis in CP patients. Supplementation 
of vitamin K might be considered when treating patients with vitamin D deficiency.  
Importantly, almost two-thirds of CP patients had osteopathy - with a rate of osteopenia of 
42% and a rate of osteoporosis of 22%. This finding confirms the importance of the 
recommendation of international guidelines that CP patients represent a high-risk group for 
osteoporosis in need for dual-energy X-ray absorptiometry.(17) Vitamin deficiencies should 
be corrected and the therapy of osteoporosis should follow current guidelines to prevent the 




6.3 Paper III 
The frequency of exocrine pancreatic insufficiency was studied in 20 patients with Crohn's 
disease. Pancreatic involvement in inflammatory bowel disease (IBD) is regarded as an 
extraintestinal manifestation (EIM). (105) EIM are frequent in IBD with an occurrence of 6% 
to 47% in IBD patients. The pathophysiology of EIM is still ill-defined but data suggest that 
mucosal inflammation triggers autoimmune responses due to cross reactivity with epitopes of 
intestinal bacteria. Several studies suggest that genetic risk factors contribute to EIM. The 
most important EIM include musculoskeletal forms (affecting joints), cutaneous forms 
(erythema nodosum, pyoderma gangrenosum) and oral lesions (aphthous stomatitis), ocular 
manifestations (scleritis, episcleritis, and uveitis) and hepatobiliary forms (PSC). (106, 107)  
Pancreatic involvement in IBD has a large spectrum that involves simple elevation of 
pancreatic enzymes, acute and chronic pancreatitis, including autoimmune pancreatitis.  
Population-based studies indicate that the risk for acute pancreatitis is higher in IBD patients. 
(108-110) 
The increased risk in Crohn's disease can be explained by an increased risk for biliary 
pancreatitis due gallstones. A significantly decreased reabsorption of biliary salt in the 
terminal ileum is present in patients with ileocecal resection or active inflammation of the 
terminal ileum.  
Anti-inflammatory medications (particularly azathioprine) trigger transient asymptomatic 
elevations of pancreatic enzymes (amylase/lipase) but can additionally induce acute 
pancreatitis with abdominal pain and/or morphological changes that are compatible with acute 
pancreatitis. Up to 10% of all patients with chronic pancreatitis have an autoimmune 
pancreatitis, which can be divided into IgG4 positive AIP type 1 and IgG4 negative AIP type 
2. Particularly patients with type 2 AIP have a significantly increased risk to develop 
ulcerative colitis. Only limited data is available regarding the risk for chronic pancreatitis in 
IBD. Compared to the general population, alcohol plays a less prominent role in IBD-
associated chronic pancreatitis.  
Several studies evaluated the prevalence of exocrine pancreatic insufficiency with large 
variations (ranging from 18 to 80%). Results are summarized in Table 9.  
Different tests were applied to investigate PEI. 
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Direct function tests (DFTs) were used to sample duodenal fluid after pancreas stimulation 
with hormones (secretin and/or pancreozymin) or a meal (Lundh test). Collecting duodenal 
fluid is performed by fluoroscopic placement of a catheter into the duodenum or by collecting 
duodenal fluid via aspiration with a gastroscope. DFTs enable the measurement of 
concentrations of bicarbonate and pancreatic enzymes but have the disadvantage of 
invasiveness.  
This is one of the reasons that indirect function tests (IDFTs) such as the N-benzoyl-L-
tyrosyl-p-aminobenzoic (NBT-PABA) test or the fecal-elastase test are preferred. The fecal 
elastase test is the recommended method to test for PEI according to a recent EU guideline 
and represents nowadays the most widely used method to evaluate the presence of PEI. (17) 
The test is an enzyme-based immunosorbent assay (ELISA),  is non-invasive and only a very 
small sample of feces is required for analysis.  
Based on our analysis in 20 patients with Crohn's disease, we could not confirm an increased 
risk for PEI in CD. A limitation of the study was the limited number of patients. In addition, 
all CD patients were in remission. According to previous studies, PEI seems to be related to 
extension of Crohn’s disease, to location (ileal inflammation) and to the presence of active 
inflammation. (52) Active jejunal inflammation may impair stimulation of the pancreatic 
secretion via decreased enterokinase activity. (111) 
False-positivity of the fecal-elastase test has been taken into account: in watery diarrhea the 
test becomes positive due to dilution. (112) This is of particular importance when 
investigating PEI in IBD patients. In a study by Maconi, fourteen IBD patients with low FE-1 
were followed up with a second FE-1 test after 4-6 months and normalization of FE1 was 
noted in two-thirds (10/14) of patients. (113) 
We are well-aware of the limitations of the FE-1 test. Normal FE-1 levels can exclude the 
presence of PEI with high certainty but the cut-off values to define PEI are still subject to 
debate. In addition, the FE-1 test proved to have a low sensitivity to detect a mild to moderate 
exocrine pancreatic insufficiency. (114) Consequently, we cannot exclude asymptomatic 





Table 9. Studies investigating pancreatic dysfunction in IBD patients.  
 
AUTHOR YEAR N PATIENTS TEST RESULTS 
Angelini(115) 1988 17 13 males, 4 females; 
mean age 34.6 years 
(range 17-70 years); 




Bicarbonate and enzyme 
insufficiency in 4 out of 17 
(23.5%) patients with CD 
and an enzyme 
insufficiency in 2 (11.7%) 
others 
Hegnhoj(116)  1990 143 59 males, 84 females; 
mean age 37 years  
(range 15-80 years); 





activities of amylase and 
lipase in duodenal aspirates. 
Disease activity and 
localization or extent of CD 
seems to be responsible for 
impaired pancreatic 
function 
Heikius(117) 1996 46 Mean age of the whole 
group of IBD patients 
was 43.5 years and the 











12 patients with low NBT-
PABA test; 3 patients with 
abnormal secretin test 
Seibold(118) 1996 64 37 females and 27 males; 
mean duration of CD 8.8 
years; mean age 38 years 
(range 16-68 years)  
Chymotrypsin Seven of the PAB-positive 
patients (27%) had 
impaired pancreatic 
function, in contrast to 
three of 38 PAB-negative 
patients (8%)  
(p < 0.05). 
Barthet(119) 2005 71  In total 71 patients with 
CD were included; 
among them 49 patients 
without history of 
pancreatitis; mean 
duration of CD 10.3 
years; 
median age 36 years  
FE-1 FE-1 was low in 17% of 
patients without previous 
history of pancreatitis 
Maconi(113) 2007 100 55 females; 45 males 
mean age 41.4 years  
FE-1 14 patients with low FE-1; 
normalization of FE1 in 10 
out of 14 patients after 4-6 
months; 
no significant association 
was found between PEI and 
other clinical variables. 
Malluta(120) 2019 51 28 females, 23 males; 
mean age 38 years 
(range 18-59 years); 
mean duration of CD 84 
months   
FE-1 4 (7.8%) patients with low 
levels of FE-1: all of them 




6.4 Paper IV 
According to our study with the inclusion of 57 patients, Sjögren´s syndrome does not appear 
to be associated with an increased risk for PEI. All patients who performed FE-1 testing 
and/or a 13C-mixed triglycerides (13C-MTG) breath test had normal results.  
Several previous studies stated an increased prevalence of pancreatic exocrine dysfunction. 
(33, 65). Different diagnostic methods were applied in rather small cohorts of SS patients and 
frequently control groups were lacking. It is of note that PEI had not been strictly defined. We 
defined PEI as a significant reduction of enzyme activity in the GI tract resulting in 
maldigestion according to a current EU guideline. (17) According to this concept, minor 
reductions of enzyme activity do not play a significant clinical role.   
In contrast, in our study of 57 patients with Sjögren´s syndrome, the most widely used test for 
diagnosing PEI - namely the fecal elastase-1 test - was in all patients normal. Moreover, in all 
tested patients the 13C-mixed triglycerides (13C-MTG) breath test was normal. The test 
delineates maldigestion of 13C-marked triglycerides in the presence of a prominent lipase 
deficiency and is a recommended method to investigate PEI according to a recent EU 
guideline. (17) 
As a limitation, only one-third of the included SS patients agreed to conduct a breath-test. To 
increase the acceptance rate, a short version of the 13C-MTG breath test was used which was 
shown to have similar rates of sensitivity and specificity. (11) 
The aim of our study was to detect clinically relevant pancreatic exocrine insufficiency due to 
a prominent reduction of enzyme activity. Our chosen methods are not suitable to detect 
minor pancreatic dysfunction.  
Importantly, we systematically evaluated GI symptoms in all SS patients and compared the 
prevalence and severity of 11 items with a control group that was derived from more than 
1000 randomly contacted subjects from Stockholm (PopCol study). The large majority of 
patients had IBS-like GI symptoms consisting of feeling of incomplete emptying after 
defecation, relief of abdominal pain after bowel movement, constipation and diarrhea.  
This is the first study that systematically investigated a large range of IBS-like GI symptoms 
in a well-characterized cohort of primary SS patients compared to a strict sex and age 
matched control. According to our data, SS patients harbor a significant risk of developing 
severe IBS-like GI symptoms. Based on our findings, the high prevalence of GI symptoms in 
SS cannot be attributed to exocrine pancreatic insufficiency.
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7. FUTURE PERSPECTIVES 
 
Meta-analyses and systematic reviews are valuable methods to summarize previous studies 
within a topic of interest before starting a new study in a similar area of research. We 
published our study in 2016 and it would be of great interest to conduct a new meta-analysis 
on the basis of larger and more homogeneous studies to generate more reliable results.  
In our second study we included the analysis of vitamin K which is an important factor in 
bone metabolism. There is still limited data regarding vitamin K deficiency in this group of 
patients with chronic pancreatitis. Therefore, it is worthwhile to plan new prospective studies 
including age and sex matched controls in order to determine the risk for deficiencies of fat-
soluble vitamins and micronutrients. This would enable us to get a more objective picture of 
deficiency rates in patients with CP compared to control subjects.  
Besides measuring markers of maldigestion, such prospective studies should include the 
analysis bone mineral density, sarcopenia and other important risk factors (such as 
cardiovascular complications).  
 
The following concrete questions may be addressed in future studies: 
How many patients with newly diagnosed untreated PEI have vitamin deficiencies compared 
to controls? 
How many CP patients with PEI and ongoing enzyme replacement therapy have ongoing 
vitamin deficiencies?  
Are rates of deficiencies related to the daily oral dose of enzymes? 
Are deficiency rates in CP patients higher in more advanced CP? 
Is the risk vitamin deficiencies in CP patients dependent on the etiology of CP? 
What is the risk for vitamin deficiencies in CP patients with ongoing alcohol misuse 
compared to abstinent CP patients with former alcoholism? 
The important impact is information of PERT and the dosage and quality of life questions 
which is missing in our studies. Because of shorter median survival time and increased risks 
of comorbidity and mortality risks it would be an interesting aspect to do a long cohort study 
in this patient group with regular controls of fat soluble vitamins and micronutrients which 




There is accumulating evidence demonstrating a prominent role of the intracolonic 
microbiome in modulating a large range of gastrointestinal diseases. Studies investigating 
microbiota in patients with CP and IBD patients could be of interest even when focusing on 
exocrine pancreatic insufficiency and its complications. It would be a promising idea to 
investigate possible correlations between osteoporosis, vitamin K levels and the microbiome.  
 
Based on our study in patients with Crohn´s disease who were all in remission a new study 
with the inclusion of patients with Crohn´s disease and active small bowel inflammation 
would be of interest. This study could further clarify the concept that mucosal inflammation in 
the small bowel leads to pancreatic dysfunction and possible pancreatic exocrine insufficiency 
due to impaired stimulation of the pancreas.  
 
Finally, future studies are warranted to delineate the underlying etiology of gastrointestinal 
symptoms in SS patients which may include studies of enteral dysmotility and interventional 
studies targeting IBS. We support the concept that gastroenterologists are included into the 
multidisciplinary team when taking care of patients with Sjögren´s syndrome.  
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8. POPULÄRVETENSKAPLIG SAMMANFATTNING 
Kronisk pankreatit är en progressiv inflammatorisk sjukdom av bukspottkörteln som 
kännetecknas av fibros och irreversibla morfologiska förändringar som så småningom kan 
leda till permanent förlust av såväl exokrin som endokrin funktion.  
Etiologin till kronisk pankreatit är multifaktoriell. De vanligaste faktorerna är alkohol och 
rökning. Andra orsaker är ärftliga (mutationer i PRSS1 eller SPINK1), anatomiska (pankreas 
divisum, obstruktion av pankreasgången, pankreaskirurgi), immunologiska (autoimmun 
pankreatit) och sällsynta metabola (hyperkalcemi, toxiner) faktorer och medfödda tillstånd 
såsom cystisk fibros (CF) som beror på mutationer i genen CFTR.  
Exokrin pankreasinsufficiens (EPI) uppstår när 90 % av det pankreatiska parenkymet 
förloras. Kliniska symtom på EPI uppvisas vanligtvis inte förrän nivåerna av 
matsmältningsenzymer i pankreas faller under 10 % av den normala nivån och den 
resulterande maldigestionen av de intagna näringsämnen leder till näringsbrist. 
 
Ett bra screeningtest för att bekräfta klinisk misstanke om exokrin pankreasinsufficiens är 
mätning av elastas i feces (f-elastas). F-elastas är stabilt under hela passagen genom tarmen i 
kontrast till lipas och amylas som degraderas. F-elastas analysen är enkel, snabb, icke-invasiv, 
påverkas inte av samtidigt intag av pankreasenzymer och kan genomföras med ett enkelt 
avföringsprov. Generellt anses f-elastas <200 μg/g avföring som patologisk och förenlig med 
EPI.  
Ett indirekt test som används för att diagnostisera EPI är en magnetkameraundersökning 
(MRCP) efter stimulering av pankreas sekretion med sekretin. Denna metod visualiserar 
volym av pankreassaft i tolvfingertarmen, men ger ingen direkt information om 
enzymfunktionen. Bilden hänvisar till vätskeproduktion (ekvivalent med 
bikarbonatsekretionen) som dock korrelerar väl med enzymproduktion. 
13C-MTG (mixed triglycerid) utandningstest anses vara ett mer känsligt test för att 
diagnostisera EPI än FE-1-mätning och som specifikt kvantifierar förmågan att metabolisera 
triglycerider. Vid EPI har utsöndringen av pankreassaft sjunkit under den nivå som krävs för 
en normal matsmältning. Vid 13C-MTG utandningstest intas triglycerider som innehåller 
fettsyror som markerats med kol-isotopen 13C (normalt kol är 12C). Kol-isotopen 13C är en 
stabil kol-isotop som förekommer naturligt, men i relativt låg koncentration. När de 13C-
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märkta triglyceriderna når tunntarmen bryts de ner av pankreasenzymet lipas till 
monoglycerider och fria fettsyror. Fettsyrorna tas upp av tarmslemhinnan och efter 
metabolism i levern bildas 13CO2 som sedan andas ut och samlas i påsar för analys. Vid 
bristande lipasproduktion blir koncentrationen av 13CO2 lägre i utandningsluften och exokrin 
pankreasinsufficiens kan på detta sätt påvisas och kvantifieras. 
När diagnosen EPI är ställd får patienten en oral substitution av pankreasenzymer i form av 
kapslar som kompenserar enzymbristen. 
 
I delarbete I genomförde vi en systematisk granskning och metaanalys av förekomsten av 
brist på fettlösliga vitaminer hos patienter med CP. Projektet utformades som ett 
internationellt samarbete mellan gastroenterologer från olika länder, däribland Estland, 
Tyskland, Italien, Polen, Spanien och Sverige. Databasen MEDLINE söktes fram till januari 
2016 för case series och case-control studier som rapporterade förekomsten av eventuell 
fettlöslig vitaminbrist hos CP-patienter. Frekvensen av vitaminbristen analyserades och 
förekomsten av vitaminbrist  mellan CP och kontroller jämfördes genom statistiska 
beräkningar (relativ OR och 95% konfidensintervall). 
Tolv artiklar med totalt 548 CP-patienter inkluderades i denna metaanalys. De sammanlagda 
frekvenserna av vitamin A, D och E-brist var 16,8%, 57,6% och 29,2%. Endast en studie 
utvärderade vitamin K-brist. Pooled OR för vitamin D brist var jämfört med kontroller har 
varit 1.17 (95% CI 0.79 - 1.78). 
Brist på fettlösliga vitaminer är frekvent hos CP-patienter, men det finns stor heterogenitet 
mellan olika studier. När det gäller vitamin D finns det bara få studier som hade en 
kontrollgrupp och denna metaanalys visade ingen uppenbar ökad risk hos CP patienter att ha 
vitamin D brist. Viktig är att nämna att information har varit ofta begränsad hur många av CP 
patienterna har haft en exokrin pankreasinsufficiens och hur många fick en oral behandling 
med pankreasenzymer. Större och mer homogena studier är nödvändiga för att bättre 
uppskatta förekomsten av fettlösliga vitamin brister, med särskilt fokus på vitamin K. 
 
Målet i delarbete II har varit att utvärdera förekomsten av osteoporos och osteopeni hos 
patienter med kronisk pankreatit i en stor, homogen population enligt standardiserade 
diagnoskriterier. Det andra syftet med denna studie är att bedöma sambandet mellan bentäthet 
och kännetecken på kronisk pankreatit, och näringsmässiga parametrar, speciellt vitamin D 
och K. Projektet utformades som ett internationellt samarbete mellan gastroenterologer från 
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olika länder, däribland Estland, Tyskland, Italien, Polen, Spanien och Sverige. Det är en del 
av utbildnings- och forskningsprogrammet "Pancreas 2000". Vi genomförde en multicenter 
tvärsnittsstudie (P-BONE studie) och analyserade patienter med kronisk pankreatit där vi 
registrerade klinisk information och olika biokemiska variabler. Exokrin pankreasinsufficiens 
fastställdes genom fekal elastas-1 (FE-1). En systematisk bentäthetsmätning utfördes genom 
en DXA-undersökning (dual-energy X-ray absorptiometry/DEXA). Statistiska metoder 
genomfördes med hjälp av Fishers exakta test och genom t-test. 
211 patienter med kronisk pankreatit inkluderades (67% män, medelålder 60 år). Osteopeni 
diagnostisterades i 42% av fallen och osteoporos i 22% av alla CP patienter.  
43% av CP patienter har haft en bakomliggande alkoholöverkonsumtion, 18% av patienterna 
hade svår kronisk pankreatit och 56% hade exokrin pankreasinsufficiens. Medelvärdet av 
vitamin D var 21 ng/ml och 56% av fallen hade D-vitaminbrist. Det fanns ingen korrelation 
mellan D-vitaminnivåer, eller fekal elastas-1-nivåer och bentäthet (t-poäng på ryggrad eller 
lårben). Föreliggande data bekräftar en hög förekomst av osteopati hos patienter med kronisk 
pankreatit och ökad förekomst av osteoporos hos manliga patienter med K-vitaminbrist. 
Crohns sjukdom (CD) är en kronisk inflammatorisk tarmsjukdom som främst drabbar 
tarmen men kan även drabba organsystem. Pankreas engagemang i CD kan orsakas av 
förändringar i pankreasgången, minskade hormonsignaler på grund av en inflammerad 
slemhinna i tarmen och av autoimmuna extraintestinala processer. Tidigare studier som 
undersökte prevalensen av EPI hos patienter med CD har visat motstridiga resultat och 
prevalensen varierar från 18 till 80 % i litteraturen. Kraftig varierande resultat kan bara delvis 
förklaras med att olika metoder har använts för att ställa diagnosen EPI och att olika urval av 
patienter har genomförts (selektionsbias). För att närmare kartlägga om det finns en risk för 
EPI hos CD patienter har vi genomfört en pilotstudie.  
Vi genomförde en tvärsnittsstudie hos patienter med CD där vi registrerade klinisk 
information och biokemiska variabler. Alla inkluderade patienter har varit i remission. EPI 
fastställdes genom FE-1 som definieras som FE-1 <200 μg/g och 20 CD-patienter 
inkluderades (65 % män, medelålder 48 år). I alla patienter har varit FE-1 normal. I vår studie 
kunde vi visa att CD-patienter som är i remission inte verkar ha en ökad risk för exokrin 
pankreasinsufficiens. Vi bestämde oss för att inte fortsätta med studien då alla patienter hade 
normal FE-1. Större prospektiva studier är nödvändiga för att bättre uppskatta prevalensen av 




Sjögrens syndrom (SS) är en kronisk autoimmun systemsjukdom med okänd etiologi som 
företrädesvis drabbar kroppens exokrina körtlar, såsom saliv- och tårkörtlar. Upp till 30% av 
patienter har även extraglandulära symptom. Patienter med primär SS har inga andra 
reumatiska sjukdomar, däremot kan SS vara kombinerad med tex. reumatoid artrit eller 
systemisk lupus erythematosus (sekundär SS). Pankreas och spottkörtlar är funktionellt och 
histologiskt jämförbara och därför ville vi undersöka om patienter med Sjögrens syndrom har 
en även en ökad risk för en nedsatt pankreasfunktion.  
Vi genomförde en tvärsnittsundersökning hos patienter med primär SS som har rekryterats 
från en väl karakteriserad kohort i Stockholm. EPI fastställdes genom FE-1 och 13C-MTG 
(mixed triglyceride) utandningstest. EPI definieras som FE-1 <200 μg/g och kumulativa 
värden 13C-MTG (mixed triglyceride) utandningstest <20.9% efter 5 timmar. 
Gastrointestinala symptom har vi utvärderat genom en etablerad frågeformulär (GSRS). 
Resultaten av frågeformuläret jämfördes med kön och åldersmatchade kontroller. Femtiosju 
patienter med primär SS inkluderades i studien som omfattade 92% kvinnor med en 
medianålder på 63 år. Totalt 87% (50/57) av SS-patienter testades för FE-1 och alla hade 
normala resultat. Alla patienter som genomgick en 13C-MTG-BT (37%, 21/57) hade en 
normal kumulativ 13C-utandning (> 20,9% efter 5 timmar).  
Majoriteten av SS patienter har haft svåra gastrointestinal symptom och jämfört med 
kontrollgrupper fanns en signifikant skillnad i alla elva gastrointestinala parametrarna 
(p<0,01). Samma antal patienter noterade måttliga till svåra lösa avföringar (38%) och 
förstoppning (38%). Alla GI-symptom parametrar jämfördes mellan SS patienter och 
kontroller och de symptom med de största skillnader har varit: uppblåsthet (OR: 27,9; 95% 
CI: 9,81-91,9), känsla av ofullständig tömd tarm efter avföring (OR 21,4, CI 95 %: 6,95-75,8) 
och buksmärtor som minskade efter tarmtömningen (OD 17,8, 95% CI: 6,04-62,2). 
 
I vår studie kunde vi visa att den stora majoriteten av SS-patienter hade IBS-liknande GI-
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